id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2646955,7fcfa42e-7a57-4e0e-bf45-d7c0f7791c80,2A,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2021,second_quarter,HCR,"H.R. 1319, American Rescue Plan of 2021 implementation
S. 1260, U.S. Innovation and Competition Act of 2021

no specific bills, health care reform, Biosimilars, FDA policies, Innovation, 340B, comparative effectiveness research, non-interference, opioids, pandemic preparedness","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2021-07-19T14:05:28.917000-04:00
2646956,7fcfa42e-7a57-4e0e-bf45-d7c0f7791c80,2A,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2021,second_quarter,MMM,"Medicare and Medicaid Drug Reimbursement, Medicaid Rebate, Medicare Part D Non-Interference, health care reform, biosimilars, 340B, Sunshine, discount cards, MedPAC, coding, ASP, Part B, prescription drug access and affordability, transparency, international reference pricing, Stark & anti-kickback policies, home infusion, covid therapeutics and Medicare drug card

H.R. 1319, American Rescue Plan of 2021 implementation","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2021-07-19T14:05:28.917000-04:00
2646957,7fcfa42e-7a57-4e0e-bf45-d7c0f7791c80,2A,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2021,second_quarter,PHA,"H.R. 1319, American Rescue Plan of 2021 implementation


no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency

no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2021-07-19T14:05:28.917000-04:00
2646958,7fcfa42e-7a57-4e0e-bf45-d7c0f7791c80,2A,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2021,second_quarter,TAX,tax reform implementation,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2021-07-19T14:05:28.917000-04:00
2646959,7fcfa42e-7a57-4e0e-bf45-d7c0f7791c80,2A,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2021,second_quarter,BUD,"deficit reduction, appropriations, ARPA-H

S. Con Res. 5 (117)","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2021-07-19T14:05:28.917000-04:00